AI
Friday, November 09, 2018 8:11:26 AM
CLDX - .38 Pre-market now at .39/.4299
Celldex Presented Promising Interim Data from Phase 1 Study Of Differentiated CD40 Agonist CDX-1140 At The Society For Immunotherapy Of Cancer's 33rd Annual Meeting
Celldex Presented Promising Interim Data from Phase 1 Study Of Differentiated CD40 Agonist CDX-1140 At The Society For Immunotherapy Of Cancer's 33rd Annual Meeting
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
